Sovaldi
-
Gilead Pricing Strategy For Hepatitis C Drug Sovaldi Focused on Maximizing Profits Not Patients: Report
-
FDA Embroiled In Legal Battle Over Gilead Hepatitis C Drug Trial
-
China Rejects Patent Application Of Gilead For $1,000 A Day Hepatitis C Drug Sovaldi
-
Gilead Fights For Hepa C Drug Patents: Activists Concerned About Drug Accessibility
-
Achillion Posts Postive Results In Hep C Treatment Trial
-
Gilead Sciences and CVS Partner for Hepatitis C Drug
-
Expensive Sovaldi drug for hepatitis C still most cost-effective choice for U.S. prisons: Study
-
FDA approves Gilead's Harvoni drug: Can we afford the $1125 once-a-day Hepatitis C pill?
-
Expensive hepatitis C drug Sovaldi to be made cheaper in developing countries
-
Hepatitis C drug Sovaldi gets NICE approval despite being pricey
-
Gilead shoves off Roche’s claim on Sovaldi hep C drug
-
Sovaldi hepatitis C drug at $84,000 per treatment course sparks healthcare concerns
Most Popular
